SC
LEGN icon

Samlyn Capital’s Legend Biotech LEGN Stock Holding History

Samlyn Capital’s Portfolio LEGN Stock Details LEGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-407,546
Closed -$27.4M – 105
2023
Q3 		$27.4M Buy
407,546
+126,445
+45% +$8.78M 0.45% 68
2023
Q2 		$19.4M Sell
281,101
-317,327
-53% -$20.7M 0.33% 65
2023
Q1 		$28.9M Buy
598,428
+318,838
+114% +$15.6M 0.52% 55
2022
Q4 		$14M Sell
279,590
-611,922
-69% -$29.6M 0.27% 65
2022
Q3 		$36.4M Buy
891,512
+437,505
+96% +$20.5M 0.68% 46
2022
Q2 		$25M Buy
+454,007
New +$19.2M 0.5% 52
2020
Q3 		– Sell
-100,000
Closed -$4.26M – 159
2020
Q2 		$4.26M Buy
+100,000
New +$3.91M 0.08% 94

Other funds holding LEGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Samlyn Capital's LEGN Position: Q4 2023 in Review

Samlyn Capital sold out of Legend Biotech (LEGN) in Q4 2023, closing a stake of 407,546 shares — an estimated $27.4M sold.

Samlyn Capital first reported a position in LEGN in Q2 2020 and held it in 7 quarters. The position peaked at $36.4M in Q3 2022. 206 funds tracked by Wall St. Rank hold LEGN as of Q4 2023.

  • Samlyn Capital reported no remaining Legend Biotech position as of Q4 2023 after selling out during the quarter.
  • Samlyn Capital sold 407,546 Legend Biotech shares in Q4 2023, an estimated $27.4M.
  • Samlyn Capital first reported a position in Legend Biotech in Q2 2020 and held it in 7 quarters.
  • Samlyn Capital's Legend Biotech position peaked at $36.4M in Q3 2022.
  • 206 funds tracked by Wall St. Rank held Legend Biotech as of Q4 2023.

Based on Samlyn Capital's 13F filing for Q4 2023, filed 14 Feb 2024.